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1. Introduction
Stem cells are undifferentiated cells defined by their abilities to self-renew and differentiate
into mature cells. Stem cells found in fully developed tissues are defined as adult stem cells.
The function of adult stem cells is the maintenance of adult tissue specificity by homeostatic
cell replacement and tissue regeneration (Wagers and Weissman, 2004). Adult stem cells are
presumed quiescent within adult tissues, but divide infrequently to generate a stem cell
clone and a transiently-amplifying cell. The transiently-amplifying cells will undergo a lim‐
ited number of cell divisions before terminal differentiation into mature functional tissue
cells. The existence of adult stem cells has been reported in multiple organs; these include:
brain, heart, skin, intestine, testis, muscle and blood, among others. This chapter focuses on
four adult stem cell populations: hematopoietic, mesenchymal, periodontal ligament-de‐
rived, and spermatogonial (Table 1).
Hematopoietic stem cells are the most characterized adult stem cell population. They func‐
tion to generate all cell lineages found in mature blood (erythroid, myeloid and lymphoid)
and to sustain blood production during the entire life of an animal (Kondo et al., 2003).
Adult bone marrow, umbilical cord blood and mobilized peripheral blood are sources of
hematopoietic stem cells for transplantation in many blood-related diseases. Hematopoietic
stem cells can be characterized by positive selection of CD34, CD45, and CD133 markers and
negative selection of CD31, CD105 and CD146 markers (Tárnok et al., 2010).
Mesenchymal stem cells, also called marrow stromal cells, are another well-studied adult
stem cell population. Mesenchymal stem cells were originally identified in the bone mar‐
row, but have since been found in other systems such as adipose tissue, umbilical cord and
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menstrual blood (Ding et al., 2011). Mesenchymal stem cells differentiate into osteocytes,
chondrocytes and adipocytes (Arita et al., 2011; Pittenger et al., 1999). Human mesenchymal
stem cells can be characterized by the positive expression of CD29, CD44, CD73, CD90,
CD105, CD146 and STRO-1, and the negative expression of CD31, CD34, CD45, CD49f and
CD133 (Mödder et al., 2012; Tárnok et al., 2010).
Adult stem cells Feasible sources Characterization
Hematopoietic stem cells
Bone marrow, umbilical cord
blood, mobilized peripheral
blood
(+): CD34, CD45, CD133
(-): CD31, CD105, CD146
Mesenchymal stem cells Bone marrow, adipose tissue,umbilical cord, menstrual blood
(+): CD29, CD44, CD73, CD90, CD105, CD146,
STRO-1
(-): CD31, CD34, CD45, CD49f, CD133
Periodontal ligament-derived
stem cells Periodontal ligament
Mesenchymal stem cell markers: CD29, CD44,
CD73, CD90, CD105, CD146, STRO-1
Neural crest cell markers: p75, nestin, Slug,
SOX10
Spermatogonial stem cells Testis (+): CD9, CD49f and GPR125
Table 1. Feasible sources and characterization of adult stem cells
Periodontal  ligament,  derived  from  the  cranial  neural  crest,  is  a  soft  connective  tissue
embedded between the tooth root and the alveolar bone socket,  supporting the teeth in
situ  and preserving tissue homeostasis. The periodontal ligament contains stem cell pop‐
ulations that can differentiate into cementum-forming cells or bone-forming cells (Seo et
al.,  2004).  Periodontal  ligament-derived stem cells  are  heterogeneous,  composed of  mes‐
enchymal  stem cells  and putative  neural  crest  cells.  Therefore,  human periodontal  liga‐
ment-derived  stem  cell  populations  have  been  characterized  not  only  by  mesenchymal
stem cell  markers,  but  also  by  neural  crest  cell  markers,  such  as  p75,  nestin,  Slug  and
SOX10 (Huang et al., 2009; Mrozik et al., 2010).
Testicular spermatogonial stem cells are the germ-line cells for spermatogenesis, an ongoing
process throughout the lifespan of the male animals. They are unipotent in nature and con‐
tinuously generate differentiating daughter cells for subsequent production of spermatozoa
(Fagoonee et al., 2011). Human spermatogonial stem cells can be purified by antibodies
against cell surface markers CD9, CD49f and GPR125 (Conrad et al., 2008).
2. Pluripotent stem cells
Pluripotency refers  to  the  ability  of  cells  to  self-renew and differentiate  into  all  3  germ
layers  (ectoderm, endoderm and mesoderm).  Pluripotent  stem cells  are  the origin of  all
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somatic  and  germ-line  cells  in  the  developing  embryo.  The  first  pluripotent  cells  were
derived  in  1976  from  a  type  of  germ-line  tumor  known  as  a  teratocarcinoma  (Hogan,
1976).  Embryonic  stem  cells,  derived  from  the  inner  cell  mass  of  a  blastocyst  prior  to
gastrulation,  are  still  considered  the  gold  standard  for  pluripotent  stem  cells.  Even
though adult  cells  are  terminally differentiated,  pluripotency has also been conferred to
these cells in past studies, by the technique of somatic cell nuclear transfer (Perry, 2005),
parthenogenesis of unfertilized eggs (Brevini et al., 2008), and reprogramming by cell fu‐
sion (Pralong et al., 2006). Research into adult cell pluripotency was slow to progress un‐
til  a  major  breakthrough in 2006 brought  with it  the  technique of  “induced pluripotent
stem cells”. In this process adult skin fibroblasts were induced into a pluripotent state by
the forced expression of key transcription factors (OCT4, SOX2, KLF4 and c-MYC; Taka‐
hashi et al., 2007) or (OCT4, SOX2, NANOG and LIN28; Yu et al., 2007). Despite the low
reprogramming efficiency, this has become a convenient method for generating new plu‐
ripotent stem cell lines for research from differentiated adult cells.
Adult  stem  cells  are  thought  to  be  tissue-specific  and  only  able  to  differentiate  into
progeny  cells  of  their  tissues  of  origin.  An  increasing  number  of  studies,  however,  re‐
port  that  adult  stem cells  are  capable  of  giving rise  to  cells  of  an entirely  distinct  line‐
age.  The  concept  of  adult  stem  cell  plasticity  might  be  explained  by  5  potential
mechanisms:  cell  fusion,  trans-differentiation,  de-differentiation,  heterogeneous  stem cell
populations,  or  pluripotency  (Wagers  and Weissman,  2004).  Cell-cell  fusion  occurs  at  a
low  frequency,  but  is  implicated  in  the  transplantation  of  bone  marrow  cells  to  liver
hepatocytes,  cardiomyocytes  and Purkinje  neurons  (Alvarez-Dolado et  al.,  2003).  In  cell
fusion  events,  the  stem  cells  acquire  the  mature  phenotype  of  the  tissue  they  are  em‐
bedded  within  and  can  be  easily  mistaken  for  correct  differentiation  of  the  transplant‐
ed  cells.  Trans-differentiation  is  a  direct  lineage  conversion  by  the  activation  of  a
dormant  differentiation  program  to  alter  the  lineage  specificity  of  the  cell.  De-differen‐
tiation is  another lineage conversion phenomenon in which a tissue-specific  cell  sponta‐
neously  de-differentiates  into  a  more  basal  multipotent  cell  and  re-differentiates  to  a
new  lineage.  While  the  heterogeneity  of  the  stem  cell  population  employed  can  ac‐
count  for  some  of  the  apparent  trans-differentiation  and  de-differentiation  events  ob‐
served in  vivo,  it  is  worth  discussing  as  a  separate  factor  in  the  resulting  multi-lineage
tissues,  which  are  often  seen  after  transplantation.  The  characterization  of  homogene‐
ous  stem  cell  populations  that  contribute  to  the  regeneration  of  one  cell  type  remains
an  active  field  of  study  for  most  cellular  therapy  applications.  Lastly,  pluripotent  stem
cells  are  present  in  adult  tissues  as  minute  sub-populations  in  certain  stem cell  niches.
Such  a  population  has  already  been  identified  and  reported  in  bone  marrow  derived
mesenchymal  stem cells  (Jiang  et  al.,  2002).  In  addition,  pluripotent  stem cells  in  adult
tissues  can  also  arise  from  remnants  of  the  migrating  neural  crest.  The  neural  crest  is
a  transient  embryonic  structure  that  affords  various  organs  with  cells  which  could  un‐
dergo  a  more  stochastic  type  of  differentiation  than  other  embryonic  progenitor  cells
(Slack,  2008).  Neural  crest  cells  are  pluripotent  and may retain  some of  their  character‐
istics  after  their  migration and engraftment into their  terminal  sites.
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3. Isolation of pluripotent adult stem cells
The expression of embryonic stem cell markers in some adult stem cells suggest a sub-popu‐
lation of pluripotent cells in these niches (Table 2). The common embryonic stem cell mak‐
ers, such as OCT4, SOX2, NANOG, KLF4, LIN28, SSEA-1, SSEA-3, SSEA-4, TRA-1-60 and
TRA-1-81, are all expressed in hematopoietic stem cells (Wang et al., 2010; Zhao et al., 2006;
Zulli et al., 2008) and mesenchymal stem cells (Anjos-Afonso and Bonnet, 2007; Jaramillo-
Ferrada et al., 2012; Riekstina et al., 2009; Sung et al., 2010). Similarly, expressions of most of
these markers, except for LIN28, have been reported in periodontal ligament-derived stem
cells, a tissue arising from the migrating cranial neural crest (Huang et al., 2009; Kawanabe
et al., 2010). Previous studies show that spermatogonial stem cells also express most of the
embryonic stem cell markers, except SSEA-3 and TRA-1-60 (Izadyar et al., 2008; Izadyar et
al., 2011; Kanatsu-Shinohara et al., 2008; Panda et al., 2011; Zheng et al., 2009). These find‐
ings suggest that pluripotent stem cells exist as sub-populations in adult stem cell reservoirs.
Embryonic stem cell marker HSC MSC PDLSC SSC
SOX2 + + + +
OCT4 + + + +
NANOG + + + +
KLF4 + + + +
LIN28 + + +
SSEA-1 + + + +
SSEA-3 + + +
SSEA-4 + + + +
TRA-1-60 + + +
TRA-1-81 + + + +
HSC: hematopoietic stem cells; MSC: mesenchymal stem cells; PDLSC; periodontal ligament-derived stem cells; SSC:
spermatogonial stem cells;
Table 2. Embryonic stem cell marker expression in different adult stem cell populations
The existence of cells with a defined pluripotency-associated phenotypic expression with‐
in adult  tissues enables  researchers  to  isolate  and purify a  homogeneous subpopulation
of  adult  pluripotent  stem  cells.  In  fact,  with  the  use  of  magnetic  affinity  cell  sorting,
adult  human mesenchymal  stem cells,  shown to  differentiate  into  endodermal,  ectoder‐
mal  and  mesodermal  cells,  were  isolated  by  antibody  against  SSEA-3  (Kuroda  et  al.,
2010).  Similarly,  stem  cells  exhibiting  the  potential  to  generate  specialized  cells  of  the
three embryonic germ layers can be isolated by positive SSEA-4 expression from human
periodontal  ligament (Kawanabe et  al.,  2010).  Furthermore,  human spermatogonial  stem
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cells,  sharing  cellular  and  molecular  similarities  with  human embryonic  stem cells,  can
be  purified  by  α6  integrin  (CD49f)  antibody  (Conrad  et  al.,  2008).  Moreover,  a  human
hematopoietic stem cell subpopulation, highly efficient in generating long-term multi-lin‐
eage grafts, can also be isolated by the same α6 integrin expression (Notta et al., 2011). In
addition, stem cells from granulocyte colony-stimulating factor-mobilized human periph‐
eral blood can divide indefinitely without reaching replicative senescence and differenti‐
ate into multiple lineages (Cesselli et al., 2009).
Recently, a cell surfaceome map of mouse embryonic stem cells and induced pluripotent
stem cells was reported (Gundry et al., 2012). Previously unidentified cellular surface mark‐
ers, such as CD31, CD49f, CD123 and CD326, indicated a purified population of pluripotent
stem cells. Further analyses should be performed to determine the expression of these mark‐
ers in different adult stem cell populations. Their presence in adult stem cell populations
could facilitate the purification of homogeneous pluripotent stem cells within an otherwise
heterogeneous pool of regenerative adult cells.
4. Characterization of pluripotent adult stem cells
The standard tests  for  pluripotency are  teratoma and chimera formation assays.  Terato‐
mas  can  be  formed when pluripotent  stem cells  are  injected  into  immunodeficient  ani‐
mals;  they  consist  of  foci  with  derivatives  of  ectodermal,  mesodermal  and  endodermal
embryonic germs layers (Wobus et  al.,  1984).  Chimeras can be generated when pluripo‐
tent stem cells  are microinjected into mouse blastocysts and are induced to differentiate
into multiple cell types during normal developmental processes (Becker et al., 1984). Ter‐
atoma  formation  assays  can  be  used  to  test  for  the  pluripotency  of  human  stem  cells,
whereas  both  teratoma  and  chimera  formation  can  test  for  the  pluripotency  of  mouse
stem cells.  Spermatogonial  stem cells  isolated from human testis  by positive  expression
of  CD49f  are  able  to  form teratomas when injected into  immunodeficient  mice  (Conrad
et  al.,  2008).  Mesenchymal  stem  cells  isolated  from  murine  bone  marrow  contribute  to
most of the somatic cell types (chimerism ranged between 0.1% and 45%) when they are
singly injected into an early mouse blastocyst (Jiang et al., 2002). Moreover, human hem‐
atopoietic stem cells isolated by CD49f cell  surface marker display multi-lineage chimer‐
ism  when  transplanted  into  the  NOD-scid-IL2Rgc-/-  mice  (Notta  et  al.,  2011).  However,
human  bone  marrow-derived  mesenchymal  stem  cells  purified  by  the  SSEA-3  cell  sur‐
face  marker  do not  form teratomas in  immunodeficient  mouse  testes  even though cells
positive  for  human ectodermal,  endodermal  and mesodermal  lineage  markers  were  de‐
tected within the injected mouse testes (Kuroda et al., 2010). Conversely, pluripotency as‐
says  of  human  periodontal  ligament-derived  stem  cells  isolated  by  SSEA-4  cell  surface
marker expression have not yet been reported (Kawanabe et al., 2010).
Although most of the adult stem cells are unable to form teratomas in immunodeficient
mice, can they still be defined as pluripotent stem cells? Considering this apparent inability
as well as the variability in teratoma formation efficiency even when using a known pluripo‐
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tent stem cell line, a teratoma assay might not be a suitable assay for pluripotency of adult
stem cells. Instead, in vitro and in vivo differentiation into cells of the 3 embryonic germ lay‐
ers along with chimera formation in xeno-transplanted mice can be applied for testing adult
stem cell potency. The conventional concept of development involves a hierarchical struc‐
ture of cellular commitment extending outward from embryonic and pluripotent, to adult
terminally differentiated tissues. However, recent ideas propose that all or most tissues in
the postnatal body are continuously turning over and contain a pluripotent stem cell reser‐
voir (Slack, 2008). These pluripotent stem cell populations are able to differentiate into mul‐
tiple cell types depending on their microenvironmental cues. Therefore, the stem cell status
should be defined by plasticity (Zipori, 2005). Pluripotency refers to the ability of cells to dif‐
ferentiate into any cell type of the 3 germ layers (ectoderm, endoderm and mesoderm),
whereas multipotency refers to the ability of cells to differentiate only into a closely related
family of cells (Ilic and Polak, 2011). All of the previously described adult stem cells (hema‐
topoietic, mesenchymal, periodontal ligament-derived, and spermatogonial) could differen‐
tiate into specialized cells of the three germ layers: neurons (ectodermal lineage), adipocytes,
cardiomyocytes, osteoblasts, and chondrocytes (mesoderm lineage), and hepatocytes and in‐
sulin-producing cells (endodermal lineage) (Conrad et al., 2008; Jiang et al., 2002; Kuroda et
al., 2010; Kawanabe et al., 2010; Notta et al., 2011). Therefore, these adult stem cells could
also be defined as pluripotent stem cells.
5. Advantages of pluripotent adult stem cells over embryonic stem cells
and induced pluripotent stem cells
Human embryonic stem cells come from the inner cell mass of human blastocysts. There‐
fore,  embryonic  stem  cells  used  for  cell  therapy  are  allogenic;  the  transplanted  donor
cells  do  not  originate  from the  recipient.  This  raises  a  concern  about  the  immunogenic
response of the host, and the need for immune-suppressive therapy concurrent with em‐
bryonic  stem cell  transplantation (Charron et  al.,  2009).  Moreover,  embryonic  stem cell-
based therapy has been hampered by the moral,  legal and ethical dilemma surrounding
the use of human embryos for derivation of the stem cell lines (Zarzeczny and Caulfield,
2009).  Furthermore,  as the gold standard of pluripotent stem cells,  embryonic stem cells
have the potential  to form teratomas in the host.  Tumorigenic potential  can be reduced
by  differentiating  the  embryonic  stem cells  into  lineage-specific  progenitor  cells  or  ma‐
ture tissue cells prior to transplantation (Schwartz et al.,  2012). In order to better control
standards  of  good  manufacturing  practices  and  reduce  variability  as  much  as  possible,
the in vitro manipulation of embryonic stem cells should be minimized as recommend by
the Food and Drug Administration (Lysaght and Campbell,  2011).  Furthermore,  tumori‐
genic  potential  remains  a  concern if  the  entirety  of  the  embryonic  stem cell  population
does not completely differentiate into fully mature cells.
Differentiated adult cells used for the generation of the induced pluripotent stem cells can
be collected from the recipient body, avoiding the contentious need for a human embryo.
This also circumvents the problem of immune rejection. There are technical hurdles, howev‐
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er, concerning generation of induced pluripotent stem cells (Hayden, 2011). Firstly, the de‐
livery of reprogramming factors (OCT4, SOX2, NANOG, LIN28, KLF4 and c-MYC) relies on
the use of viral vectors for delivery (Takahashi et al., 2007). Retroviral sequences could inte‐
grate into the DNA of the host cells, potentially disrupting the gene structure as well as re‐
sulting in an aberrant phenotypic expression. Ultimately this could result in pathological
mutations and cancer formation. Alternative methods such as direct protein or small mole‐
cule delivery have been adopted, although the reprogramming efficiency of these techni‐
ques is lower than with viral vectors (Kim et al., 2009; Shi et al., 2008). Secondly, two of the
reprogramming factors, c-MYC and KLF4, are proto-oncogenes, which raise the concern of
cancer formation further. Omitting c-MYC would lower the reprogramming efficiency,
whereas silencing c-MYC could lead to its reactivation. Moreover, reprogramming can in‐
duce other genomic changes, such as DNA mutations (Gore et al., 2011), copy number varia‐
tions (Hussein et al., 2011) and chromosomal aberrations (Mayshar et al., 2010). Genomic
instability could have unpredictable and undesirable effects on the reprogrammed cells.
Furthermore, induced pluripotent stem cells carry their epigenetic signatures from the origi‐
nal differentiated adult cells (Lister et al., 2011). The reprogrammed cells, therefore, unlike
embryonic stem cells, may not develop into some cell types. In addition, induced pluripo‐
tent stem cells can still cause immune reactions when transplanted allogeneically.
The sources of adult stem cells are multiple and feasibly obtained from various adult tissues,
such as bone marrow, blood, adipose tissue, teeth and testes (Table 1). These adult stem cells
can be collected from the human body at anytime throughout life. This makes them readily
available and does not raise the moral and ethical issues involved with the attainment of
embryonic stem cells. Moreover, pluripotent adult stem cells can easily be isolated and puri‐
fied by cell surface markers, such as CD49f, SSEA-3 and SSEA4 (Conrad et al., 2008; Kuroda
et al., 2010; Kawanabe et al., 2010; Notta et al., 2011). The pluripotent status of these adult
stem cells is naturally acquired and does not require reprogramming by the introduction of
pluripotent transcriptional factors, thus eliminating the use of viral vectors and the chance
of aberrant chromosomal changes. Furthermore, transplantation of mesenchymal stem cells
and periodontal ligament-derived stem cells can be autogenic or allogeneic. Immuno-sup‐
pression is not necessary since mesenchymal stem cells have strong immunomodulatory
properties against alloreactivity of T lymphocytes and dendritic cells (Chen et al., 2011).
Similarly, mesenchymal stem cells and periodontal ligament-derived stem cells inhibit the
proliferation of peripheral blood mononuclear cells (Wada et al., 2009). Spermatogonial stem
cells, however, are killed by cytotoxic T lymphocytes after transplantation (Dressel et al.,
2009), whereas allogeneic hematopoietic stem cell transplantation induces graft-vs-host dis‐
ease (Strober et al., 2011). Therefore, transplantation of spermatogonial stem cells and hema‐
topoietic stem cells should only be autogenic, without the application of
immunosuppressive drugs. Similar to embryonic stem cells and induced pluripotent stem
cells, pluripotent adult stem cells can differentiate into specialized cells of the three germ
layers. Except for spermatogonial stem cells (Conrad et al., 2008), teratoma formation was
not found in pluripotent hematopoietic stem cells, mesenchymal stem cells and periodontal
ligament-derived stem cells (Kuroda et al., 2010; Kawanabe et al., 2010; Notta et al., 2011).
This suggests a reduction in the probabilities of tumor formation post-transplantation, and
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the elimination of the need to manipulate the cells into mature tissue prior to transplanta‐
tion. In addition, transplanted stem cell-induced regeneration may not be due to stem cell
differentiation per se (Johnson et al., 2010; Williams and Hare, 2011). Instead, a paracrine ef‐
fect has been hypothesized in which the adult stem cells secrete cytokines, chemokines, or
protective proteins (Bai et al., 2012; Bráz et al., 2012) that nourish the host tissue cells and
facilitate the healing process. This special feature has not yet been reported with the use of
embryonic stem cells or induced pluripotent stem cells in a clinical setting.
6. Potential applications of pluripotent adult stem cells
Stem cell clinical trials have advanced rapidly for a broad spectrum of diseases, such as dia‐
betes, neurodegeneration, immune diseases, heart disease, and bone disease. In 2011, there
were 123 clinical trials using mesenchymal stem cells (Trounson et al., 2011). It is predicted
that stem cell therapy will eventually become the treatment of choice in regenerative medi‐
cine, especially the use of adult stem cells. As stem cell products become more wide-spread
and maintained under various conditions, the need for global standardization and regula‐
tion of processes will become necessary for the viable application of these products in a clin‐
ical setting. The Food and Drug Administration regulates interstate commerce in human
cells and tissue-based products under the Public Health Service Act and the Code of Federal
Regulations for Food and Drugs (Lysaght and Campbell, 2011). Human cells and tissue-
based products are defined as “articles containing or consisting of human cells or tissues
that are intended for implantation, transplantation, infusion, or transfer into a human recipi‐
ent” (Lysaght and Campbell, 2011). Human cells and tissue-based products must be: (1)
minimally manipulated, (2) intended only for homologous use, (3) not combined with an‐
other article (except for water, or sterilization, preservation, or storage agents), and (4) ei‐
ther: (a) have no systemic or metabolic effect, or (b) be for autologous use, allogeneic use in
first- or second-degree blood relative, or reproductive use.
Pluripotent adult stem cells fall under the criteria for human cells and tissue-based prod‐
ucts  as  stated  by  the  Food and  Drug  Administration.  Unlike  induced  pluripotent  stem
cells, pluripotent adult stem cells can be minimally manipulated as their pluripotent state
occurs naturally. Unlike embryonic stem cells, pluripotent adult stem cells are suited for
autologous use. Similar to embryonic stem cells and induced pluripotent stem cells, plu‐
ripotent adult stem cells are able to differentiate into specialized cells of the three germ
layers. In addition, embryonic stem cells and induced pluripotent stem cells have the po‐
tential  to  form teratomas (an unfavorable  side-effect  in  clinical  applications)  although a
recent study suggests that the teratoma-forming cells could be removed by the antibody
against  SSEA-5 (Tang et  al.,  2011).  In contrast,  most  pluripotent  adult  stem cells  do not
form teratomas in vivo, eliminating the need for preemptive differentiation of pluripotent
adult stem cells into mature specialized cells.
If stem cell-aided regeneration is not due to stem cell differentiation to replace damaged
cells (Johnson et al., 2010; Williams and Hare, 2011), pluripotent adult stem cells are favora‐
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ble over embryonic stem cells and induced pluripotent stem cells. The secretion of cyto‐
kines, chemokines, and/or protective proteins from the adult stem cells could nourish the
host tissue and facilitate the healing process (Bai et al., 2012; Bráz et al., 2012).
7. Summary
Adult  stem cells  are  found all  over  the  body.  They can be  conveniently  obtained from
different accessible tissues: bone marrow, blood, adipose tissue, teeth and testes. Pluripo‐
tent  adult  stem  cells,  which  reside  as  a  subpopulation  within  adult  stem  cells,  can  be
easily  isolated by pluripotent  cell  surface  markers,  such as  SSEA-3,  SSEA-4 and CD49f.
Moreover, pluripotent adult stem cells can be characterized by their ability to differenti‐
ate  into  cells  of  3  germ layers  (ectoderm,  mesoderm and endoderm)  as  well  as  by  the
chimera formation in xeno-transplanted mice. Pluripotent adult stem cells are better than
embryonic  stem  cells  and  induced  pluripotent  stem  cells  as  they  are  an  autologous
source,  require minimal manipulation and do not have the ability to form teratomas. In
addition, they are more appropriate to be used as a clinical product for therapeutic treat‐
ments, as a cellular replacement or secretory protein reservoir. However, there are uncer‐
tainties that still  remain unanswered. Which stem cell types are optimal for regenerative
medicine? What is  the optimal cell  number for transplantation? Should the cells  be pre‐
emptively  differentiated  or  used  as  is?  Further  research  is  needed  to  understand  the
mechanisms of stem cells in regenerating damaged tissues after transplantation.
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